الآثار الجانبية للمعالجة بالإيزوتريتينوئين.

Authors

  • محمد اسماعيل
  • جمال خدام
  • يمن القاطرجي

Abstract

تضمن هذا البحث دراسة الآثار الجانبية لدى 768 مريض تناولوا الايزوتريتنوئين لعلاج 20 مرض جلدي مختلف  تراوحت أعمارهم بين15-74سنة, توزعوا تبعاً لجرعة الايزوتريتنوئين المأخوذة حسب شدة المرض الجلدي المُعالج إلى مجموعة الجرعة المنخفضة≤0,25ملغ/كغ يومياً(32%) والجرعة المتوسطة 0,26-0,49مغ/كغ يومياً(37%) ومجموعة الجرعة العالية0,5-1مغ/كغ يوميا(31%)،لمدة 6 أشهر.خُصّص لكل مريض استمارة الكترونية ثم تم جمع البيانات منها حول الآثار الجانبية الأكثر شيوعاً ومعدل الاستجابة و النكس والاضطرابات المخبرية.

أوضحت دراستنا ان معظم المعالجين بالإيزوتريتنوئين كانوا راضين جدا عن العلاج وأغلب آثارهم الجانبية كانت قليلة وشدتها خفيفة وتناسب حدوثها طردا مع زيادة الجرعة،كما كانت مؤقتة عادة تتراجع مع استمرار العلاج.كانت الآثار الجانبية الأكثر شيوعاً في دراستنا هي جفاف وتشقق الشفتين67,3%ثم جفاف الوجه والجلد36,2%تبعه جفاف العين والأنف بنسبة22%من مجموع المرضى.كما وجدنا استجابة سريرية عالية واضحة لكل الجرعات.وتناسب حدوث النكس عكسا مع زيادة الجرعة.كما سجلت دراستنا حدوث اضطرابات مخبرية عابرة وعكوسة لدى8,07%.

This  study included side effects of 768 patients who were taking isotretinoin to treat 20 different skin diseases Aged between 15 – 74 years were divided according to the dose of isotretinoin taken and to the severity of the treated skin disease to the low dose  group  0.25 mg/kg daily (32%), and the medium dose 0.26-0.49 mg/kg daily and the high dose group was 1mg/kg daily . For 6 months, each patient was given an electronic form . The  data were collected on  about the most common side effects , response rate ,relapse and laboratory disorders . Our study was showed that most of the patients were treted with isotretinoin were very satisfied with the treatment and most of  their side effects were few and mild, it was also temporary. Cheilitis was the most commonly adverse effect reported, affecting 67.3% of users, followed by dry skin 36.2%, then dry eye and nose by 22%of the total patients .However, these were clearly dose-dependent. We also found high clinical response for all doses. The relapse rate  decreases by increasing the dose, our study also recorded transient laboratory disorders in 8.07%.

Downloads

Published

2018-11-19

How to Cite

1.
اسماعيل م, خدام ج, القاطرجي ي. الآثار الجانبية للمعالجة بالإيزوتريتينوئين. Tuj-hlth [Internet]. 2018Nov.19 [cited 2024Nov.24];40(5). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/4712

Issue

Vol. 40 No. 5 (2018): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)

<< < 1 2